Expression of Keratin 19 Is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation

Oncology

Volumn 80, Issue 3-4, 2011, Pages 278-288

  Tsuchiya, Kaoru ^a   Komuta, Mina ^b   Yasui, Yutaka ^a   Tamaki, Nobuharu ^a   Hosokawa, Takanori ^a   Ueda, Ken ^a   Kuzuya, Teiji ^a   Itakura, Jun ^a   Nakanishi, Hiroyuki ^a   Takahashi, Yuka ^a   Kurosaki, Masayuki ^a   Asahina, Yasuhiro ^a   Enomoto, Nobuyuki ^c   Sakamoto, Michiie ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Carcinogenesis; Hepatic progenitor cell; Hepatocellular carcinoma; Keratin; Needle biopsy; Radiofrequency ablation; Recurrence

Indexed keywords

CYTOKERATIN 19;

AGED; ARTICLE; CANCER RECURRENCE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; RISK FACTOR; STEM CELL; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ALPHA-FETOPROTEINS; BILIRUBIN; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-19; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 79959845312     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328448     Document Type: Article

References (27)

1. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
2. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omara M: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-1209. (Pubitemid 40328091)
3. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130. (Pubitemid 41002049)
4. Kudo M: Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010; 78: 113-124.
5. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC: Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007; 17: 684-692.
6. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW: Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137. (Pubitemid 40593921)
7. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schavo M, Garbagnati F, Marchiano A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S: Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909. (Pubitemid 39425785)
8. Izumi N, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, Himeno Y, Miyake S, Sakai T, Enomoto N: Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001; 91: 949-956.
9. Fernandes ML, Lin CC, Lin CJ, Chen WT, Lin SM: Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation. Br J Surg 2009; 96: 756-762.
10. Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V: Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol 1998; 29: 455-463. (Pubitemid 28396664)
11. Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Q, He YZ, Qin WZ, Chen RX, Yang GH, Wu B, Lu Q, Wu ZQ, Tang ZY: Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008; 14: 3850-3859.
12. Zhuang PY, Zhang JB, Zhu XD, Zhang W, Wu WZ, Tan YS, Hou J, Tang ZY, Qin LX, Sun HC: Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008; 112: 2740-2748. (Pubitemid 351969219)
13. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-857. (Pubitemid 37406966)
14. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-151. (Pubitemid 44079697)
15. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-1804. (Pubitemid 27475940)
16. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl 1):2-15. (Pubitemid 350256660)
17. Hirohashi S, Ishak K, Kojiro M, Wanless I, Theise N, Tsukuma H: Tumours of the liver and intrahepatic bile ducts; in Hamilton SR, Aaltonen LA (eds): Pathology and Genetics of Tumours of the Digestive System. Lyon, IARC Press, 2000, pp 157-202.
18. De Baere T, Rehim MA, Teriitheau C, Deschamps F, Lapeyre M, Dromain C, Boige V, Dromain C, Boige V, Ducreux M, Elias D: Usefulness of guiding needles for radiofrequency ablative treatment of liver tumors. Cardiovasc Intervent Radiol 2006; 29: 650-654. (Pubitemid 43823013)
19. Lorentzen T: A cooled needle electrode for radiofrequency tissue ablation: thermodynamic aspects of improved performance compared with conventional needle design. Acad Radiol 1996; 3: 556-563.
20. Goldberg SN, Gazelle GS, Solbiati L, Rittman WJ, Mueller PR: Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol 1996; 3: 636-644.
21. Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, Kohara K, Shigenobu S, Ishibashi K, Arima T: Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003; 97: 1253-1262. (Pubitemid 36237312)
22. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK: Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007; 33: 437-447. (Pubitemid 47324228)
23. Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, Durand F, Belghiti J, Sommacale D, Vilgrain V: Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol 2006; 186:S296-S305. (Pubitemid 46114734)
24. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA: Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 2007; 245: 435-442. (Pubitemid 46673140)
25. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430. (Pubitemid 32844200)
26. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD: Liver biopsy. Hepatology 2009; 49: 1017-1044.
27. van Sprundel RG, van den Ingh TS, Spee B: Keratin 19 marks poor differentiation and a more aggressive behavior in canine and human hepatocellular tumours. Comp Hepatol 2010; 9: 4.